Compare AANJANEYA LIFECARE with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS ASTRAZENECA PHARMA DR. DATSONS LABS/
ASTRAZENECA PHARMA
 
P/E (TTM) x -10.9 130.0 - View Chart
P/BV x 0.2 36.5 0.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
ASTRAZENECA PHARMA
Mar-18
DR. DATSONS LABS/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,278 9.8%   
Low Rs31883 3.5%   
Sales per share (Unadj.) Rs133.0228.4 58.2%  
Earnings per share (Unadj.) Rs0.210.4 1.5%  
Cash flow per share (Unadj.) Rs6.616.3 40.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.898.8 130.4%  
Shares outstanding (eoy) m31.6625.00 126.6%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.64.7 12.4%   
Avg P/E ratio x516.1104.2 495.2%  
P/CF ratio (eoy) x11.866.4 17.8%  
Price / Book Value ratio x0.610.9 5.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,47727,008 9.2%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m561,535 3.6%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m4,2115,710 73.7%  
Other income Rs m79123 64.2%   
Total revenues Rs m4,2895,833 73.5%   
Gross profit Rs m569463 122.8%  
Depreciation Rs m204147 138.7%   
Interest Rs m4300-   
Profit before tax Rs m13438 2.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6179 3.4%   
Profit after tax Rs m5259 1.9%  
Gross profit margin %13.58.1 166.6%  
Effective tax rate %48.040.8 117.6%   
Net profit margin %0.14.5 2.5%  
BALANCE SHEET DATA
Current assets Rs m6,8523,209 213.5%   
Current liabilities Rs m6,7112,070 324.3%   
Net working cap to sales %3.320.0 16.8%  
Current ratio x1.01.6 65.8%  
Inventory Days Days16172 222.4%  
Debtors Days Days31835 912.0%  
Net fixed assets Rs m3,673790 464.8%   
Share capital Rs m31750 633.2%   
"Free" reserves Rs m3,7612,419 155.5%   
Net worth Rs m4,0782,469 165.1%   
Long term debt Rs m1,6710-   
Total assets Rs m12,6334,605 274.3%  
Interest coverage x1.0NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.31.2 26.9%   
Return on assets %3.45.6 61.2%  
Return on equity %0.110.5 1.1%  
Return on capital %7.717.7 43.3%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m964300 321.8%   
Fx outflow Rs m6072,015 30.1%   
Net fx Rs m357-1,715 -20.8%   
CASH FLOW
From Operations Rs m1,34588 1,529.9%  
From Investments Rs m-2,256-94 2,409.8%  
From Financial Activity Rs m-1,200NA-  
Net Cashflow Rs m-2,111-6 37,029.8%  

Share Holding

Indian Promoters % 4.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 0.3 -  
FIIs % 1.4 15.7 8.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 9.1 1,034.1%  
Shareholders   20,807 12,856 161.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  VENUS REMEDIES  WYETH  

Compare DR. DATSONS LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Open Higher; Bajaj Finance & UltraTech Cement Top Gainers(09:30 am)

Asian stock markets are trading on a strong note today. The Hang Seng is trading up by 2% while the Shanghai Composite is up 0.6%. The Nikkei is trading higher by 0.4%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS